NEWPORT BEACH, Calif. - ELEVAI Labs, Inc. (NASDAQ: ELAB), known for its medical aesthetic products, has announced the launch of its online E-commerce platform, transitioning from a purely business-to-business model to also include direct-to-consumer sales. This move enables customers to purchase ELEVAI's physician-grade skincare products online and facilitates reordering through the new portal.
The company's E-commerce portal aims to extend the reach of its professional-grade products, which were previously available exclusively through physicians. By integrating an online sales channel, ELEVAI intends to streamline its distribution operations, potentially increasing sales through ease of access for customers and leveraging data collection for targeted marketing efforts.
ELEVAI's at-home serum, enfinityTM, which is said to feature umbilical cord-derived stem cell exosome technology, will be available for purchase via the new online store. However, their in-office product, empowerTM, will continue to be sold through professional channels only.
The company has recently reported unaudited year-over-year growth figures, with a 113% increase in Q4 sales and a 75% rise in new accounts for the same period. This growth comes amidst preparations to meet the anticipated expansion of the skincare industry.
Dr. Jordan Plews, CEO of ELEVAI, emphasized the importance of a medically-guided customer journey while also acknowledging the convenience the new E-commerce portal brings to patients. He stated that the launch is in line with the company's strategy to support its sales and marketing initiatives while maintaining the brand's integrity.
ELEVAI Labs develops topical skincare products by leveraging proprietary stem cell exosome technology. The company's expansion into direct-to-consumer sales marks a significant step in its growth strategy, as it continues to develop new products expected to be announced later this year.
The information in this article is based on a press release statement from ELEVAI Labs, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.